Immuneering Says Atebimetinib Patients Held Weight At About Twice Benchmark Rate, Linked To Longer Pancreatic Cancer Survival
Share
Why It Matters
Immuneering's cancer medicine helped patients keep their weight better than expected. When patients stayed healthier, they lived longer with pancreatic cancer.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.